<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01002235</url>
  </required_header>
  <id_info>
    <org_study_id>VMDN-001/D</org_study_id>
    <nct_id>NCT01002235</nct_id>
  </id_info>
  <brief_title>Gene Therapy for Painful Diabetic Neuropathy</brief_title>
  <official_title>A Phase I/II, Open Label, Dose-Escalation Study to Assess the Safety and Tolerability of VM202 in Patients With Painful Diabetic Peripheral Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helixmith Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helixmith Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of injecting VM202 in the&#xD;
      leg muscle in patients with painful diabetic neuropathy (DPN). The study will also assess the&#xD;
      potential of VM202 to reduce the pain associated with DPN.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral neuropathy is a serious complication of diabetes. This form of neuropathy carries&#xD;
      a high risk of pain, trophic changes and autonomic dysfunction.&#xD;
&#xD;
      Currently, there are no approved drugs or interventional strategies known to halt or reverse&#xD;
      the progression of DPN. Treatments target pain reduction, physical function improvement,&#xD;
      reduction of psychological distress, and quality of life improvements.&#xD;
&#xD;
      There is currently no effective treatment for diabetic neuropathy, and good glycemic control&#xD;
      is the only way to minimize the risk of occurrence. Clearly, it would be desirable to&#xD;
      prevent, impede, or reverse the disrupting and often life-threatening manifestations of&#xD;
      peripheral neuropathy by stimulating growth or regeneration of peripheral nerve axons.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity</measure>
    <time_frame>Day 0 post-dose, Days 14, 21, 30, 60, 90, Month 6 and 12</time_frame>
    <description>Measurement of Adverse events and serum levels of HGF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Levels</measure>
    <time_frame>Days 0, 14, 30, 60, 90, 180, 365</time_frame>
    <description>Change in pain level as measured by the VAS, SF-MPQ and BPI-DPN and the status of preexisting ulcers will also be reported.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Painful Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two divided doses of VM202 injected into the calf muscle on Day 0 and Day 14 for a total dose of 4 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two divided doses of VM202 injected into the calf muscle on Day 0 and Day 14 for a total dose of 8mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two divided doses of VM202 injected into the calf muscle on Day 0 and Day 14 for a total dose of 16mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VM202</intervention_name>
    <description>Intramuscular injections in the calf on Day 0 and Day 14.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years to 75 years&#xD;
&#xD;
          -  Documented history of Type I or II diabetes with current treatment control&#xD;
             (glycosylated hemoglobin A1c of ≤ 10.0%)&#xD;
&#xD;
          -  Diagnosis of painful diabetic peripheral neuropathy in both lower extremities&#xD;
&#xD;
          -  The physical examination component of the Michigan Neuropathy Screening Instrument&#xD;
             Score (MNSI) is ≥ 3 at Screening&#xD;
&#xD;
          -  Visual analog scale (VAS) score of ≥ 4 cm at Screening (0 cm = no pain - 10 cm worst&#xD;
             imaginable pain)&#xD;
&#xD;
          -  Stable treatment of diabetes for at least 3 months with no anticipated changes in&#xD;
             medication regimen, and no new symptoms associated with diabetes&#xD;
&#xD;
          -  Lower extremity pain for at least 6 months&#xD;
&#xD;
          -  If female of childbearing potential, negative pregnancy test at screening and using&#xD;
             acceptable method of birth control during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Peripheral neuropathy caused by condition other than diabetes;&#xD;
&#xD;
          -  Other pain more severe than neuropathic pain;&#xD;
&#xD;
          -  Progressive or degenerative neurological disorder;&#xD;
&#xD;
          -  Myopathy;&#xD;
&#xD;
          -  Inflammatory disorder of the blood vessels (inflammatory angiopathy, such as Buerger's&#xD;
             disease);&#xD;
&#xD;
          -  Active infection;&#xD;
&#xD;
          -  Chronic inflammatory disease (e.g. Crohn's, Rheumatoid Arthritis)&#xD;
&#xD;
          -  Positive HIV or HTLV at Screening&#xD;
&#xD;
          -  Positive Hepatitis B or C as determined by Hepatitis B core antibody (HBcAB), antibody&#xD;
             to Hepatitis B antigen (IgG and IgM; HbsAB), Hepatitis B surface antigen (HBsAg) and&#xD;
             Hepatitis C antibodies (Anti-HCV), at Screening or known immunosuppression or on&#xD;
             chronic treatment with immunosuppressive drugs, chemotherapy or radiation therapy&#xD;
&#xD;
          -  Stroke or myocardial infarction within last 6 months;&#xD;
&#xD;
          -  Ophthalmologic conditions pertinent to proliferative retinopathy or conditions that&#xD;
             preclude standard ophthalmologic examination:&#xD;
&#xD;
               -  Cataract surgery within 6 months of trial;&#xD;
&#xD;
               -  Vascular lesions of the anterior segment of the eye (infection or ulceration of&#xD;
                  the cornea, rubeotic glaucoma, etc);&#xD;
&#xD;
               -  Vascular lesions of the posterior segment of the eye or proliferative&#xD;
                  retinopathy, macular edema, s/p photocoagulation for macular edema or&#xD;
                  proliferative retinopathy; sickle cell retinopathy, ischemic retinopathy due to&#xD;
                  retinal venous stasis or carotid artery disease;&#xD;
&#xD;
               -  Choroidal angiogenesis; and&#xD;
&#xD;
               -  Large elevated choroidal nevi, choroidal vascular tumors (choroidal hemangioma),&#xD;
                  or melanomas.&#xD;
&#xD;
          -  Specific laboratory values at Screening including: Hemoglobin &lt; 9.0 g/dL, WBC &lt; 3,000&#xD;
             cells per microliter, platelet count &lt;75,000/mm3, Creatinine &gt; 2.0 mg/dL; GFR &lt; 50,&#xD;
             AST and/or ALT &gt; 2 times the upper limit of normal or any other clinically significant&#xD;
             lab abnormality which in the opinion of the investigator should be exclusionary;&#xD;
&#xD;
          -  Use of gamma-linolenic acid (GLA), alpha lipoic acid or any other high dose dietary&#xD;
             antioxidant supplement for symptomatic relief of DPN;&#xD;
&#xD;
          -  Uncontrolled hypertension as defined as sustained systolic blood pressure (SBP) &gt; 200&#xD;
             mmHg or diastolic BP (DBP) &gt; 110 mmHg at baseline/screening evaluation;&#xD;
&#xD;
          -  Patients with history of or new screening finding of malignant neoplasm except basal&#xD;
             cell carcinoma or squamous cell carcinoma of the skin (if excised and no evidence of&#xD;
             recurrence);&#xD;
&#xD;
          -  Malignant tumors or abnormal screening test suspicious for cancer, or patients in whom&#xD;
             screening exams indicate possible occult malignancy unless malignancy has been ruled&#xD;
             out. Patients with family history of colon cancer in any first degree relative unless&#xD;
             they have undergone a colonoscopy in the last 12 months with negative findings;&#xD;
&#xD;
          -  Elevated PSA unless prostate cancer has been excluded;&#xD;
&#xD;
          -  Subjects requiring &gt; 81 mg daily of acetylsalicylic acid; If &gt; 81 mg are taken at&#xD;
             screening, subjects may be enrolled if willing/able to switch to another medication;&#xD;
&#xD;
          -  Major psychiatric disorder in past 6 months;&#xD;
&#xD;
          -  History of drug or alcohol abuse / dependence in the past 2 years;&#xD;
&#xD;
          -  History of recent tobacco abuse (within past 5 years);&#xD;
&#xD;
          -  BMI &gt; 38 kg/m2;&#xD;
&#xD;
          -  Use of an investigational drug or treatment in past 12 months; and&#xD;
&#xD;
          -  Unable or unwilling to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Kessler, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diablo Clinical Research Hospital</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 24, 2009</study_first_submitted>
  <study_first_submitted_qc>October 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2009</study_first_posted>
  <disposition_first_submitted>January 30, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>January 30, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 9, 2015</disposition_first_posted>
  <last_update_submitted>October 16, 2019</last_update_submitted>
  <last_update_submitted_qc>October 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic</keyword>
  <keyword>Neuropathy</keyword>
  <keyword>peripheral</keyword>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

